CHRONIC FATIGUE SYNDROME TREATMENT
------------------------------------------------------------------------
NEWS RELEASE TRANSMITTED BY CANADIAN CORPORATE NEWS
FOR: HELIX BIOPHARMA CORP.
TSE, VSE SYMBOL: HBP
NOVEMBER 21, 1996
Helix BioPharma Announces Discussions with Leading
Canadian Clinic Regarding the Administration of
Ampligen(R)
RICHMOND, BRITISH COLUMBIA--Helix BioPharma Corp. is pleased to
announce that it has entered into discussions with a leading
Canadian clinic for the purpose of administering Ampligen(R) to
individuals suffering from Chronic Fatigue Syndrome (CFS). Dr.
Donald H. Segal, Helix's Vice President of Pharmaceuticals, has
said that "we want CFS patients to be treated in the proper
environment. In an established clinic the patients will receive
the best diagnosis, treatment, and follow-up on a continuous,
outpatient basis."
A recent Griffiths McBurney & Partners report stated, "because of
the lack of an effective treatment for CFS, which affects an
estimated 400,000 people in the United States alone ... the
availability of Ampligen(R) in Canada could attract CFS sufferers
from the United States and European countries, where the drug is
currently unavailable." Helix has already received numerous calls
from patients around the world inquiring as to Ampligen(R)'s
availability.
As announced in Helix's news release dated October 17, 1996,
results of a Belgium clinical study presented at the recent
scientific meeting of the American Association for Chronic Fatigue
Syndrome evidenced that the antiviral and immune modulatory drug
Ampligen(R) produced significant physical and cognitive
improvements among patients suffering from CFS. The study was
presented by Kenny De Meirleir, M.D., Ph.D., from the University
of Brussels, and by David Strayer, M.D., Professor of Medicine at
Allegheny University, PA, and Medical Director for Hemispherx
BioPharma Inc.
Helix BioPharma Corp. and Hemispherx BioPharma Inc. are
cooperating under a strategic alliance announced on April 17, 1996
to undertake the joint development of Hemispherx's product,
Ampligen(R) in Canada.
Helix BioPharma Corp. is a company which actively develops,
licenses, markets, and distributes quality bio-medical and
pharmaceutical products, technologies, and services domestically
and internationally.
Dated at Richmond, B.C. this 21st Day of November, 1996.
ON BEHALF OF THE BOARD
Terrance G. Owen, Ph.D., M.B.A., President
|
